Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell Interaction

Yang, Tianying; Li, Jiawei; Li, Ruimin; Yang, Chun‐Chen; Zhang, Weitao; Qiu, Yue; Yang, Cheng; Rong, Ruiming

doi:10.2174/1566523219666190618093707

Cited by 13 publications

(10 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent years, PD1 and PDL1 are hot spots in the immune regulation. Several studies reported that they governed pathways acting as feedback to prevent excessive T cell response ( Yang et al, 2019 ). In this study, the basal-like subtype samples showed higher expression of immune checkpoint genes (PD-L1, PD-L2, CD40, CD80, CD86, IDO1, and LAG3) than other subtypes.…”

Section: Discussionmentioning

confidence: 99%

Uncovering the Subtype-Specific Molecular Characteristics of Breast Cancer by Multiomics Analysis of Prognosis-Associated Genes, Driver Genes, Signaling Pathways, and Immune Activity

Zhou

Xiao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Breast cancer is a heterogeneous malignant disease with different prognoses and has been divided into four molecular subtypes. It is believed that molecular events occurring in breast stem/progenitor cells contribute to the carcinogenesis and development of different breast cancer subtypes. However, these subtype-specific molecular characteristics are largely unknown. In this study, we employed 1217 breast cancer samples from The Cancer Genome Atlas (TCGA) database for a multiomics analysis of the molecular characteristics of different breast cancer subtypes based on PAM50 algorithms. We detected the expression changes of subtype-specific genes and revealed that the expression of particular subtype-specific genes significantly affected prognosis. We also investigated the mutations and copy number variations (CNVs) of breast cancer driver genes and the representative genes of ten signaling pathways in different subtypes and revealed several subtype-specifically altered genes. Moreover, we detected the infiltration of various immune cells in different subtypes of breast cancer and showed that the infiltration levels of major immune cell types are different among these subtypes. Additionally, we investigated the factors affecting the immune infiltration level and the immune cytolytic activity in different breast cancer subtypes, namely, the mutation burden, genome instability and cancer-associated fibroblast (CAF) infiltration. This study may shed light on the molecular events contributing to carcinogenesis and development and provide potential markers and targets for the clinical diagnosis and treatment of different breast cancer subtypes.

show abstract

Section: Discussionmentioning

confidence: 99%

Uncovering the Subtype-Specific Molecular Characteristics of Breast Cancer by Multiomics Analysis of Prognosis-Associated Genes, Driver Genes, Signaling Pathways, and Immune Activity

Zhou

Xiao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…It has been observed that CCR5 + MDSCs could migrate to the endometriosis lesions 148 and contribute to the progression of endometriosis through enhancing the generation of arginase (ARG-1), indoleamine2,3-dioxygenase1 (IDO), inducible nitric oxide synthase (iNOS) and PD-L1. 149 , 150 The production of ARG-1 might be associated with the consumption of the amino acids that is required for the T cell function, thus, inhibiting T cells in several ways. In addition to that, both IDO and PD-L1 could act as suppressors for T cells.…”

Section: Ccl5/ccr5 and Diseasesmentioning

confidence: 99%

CCL5/CCR5 axis in human diseases and related treatments

et al. 2022

View full text Add to dashboard Cite

To defense harmful stimuli or maintain the immune homeostasis, the body produces and recruits a superfamily of cytokines such as interleukins, interferons, chemokines etc. Among them, chemokines act as crucial regulators in defense systems. CCL5/CCR5 combination is known for facilitating inflammatory responses, as well as inducing the adhesion and migration of different T cell subsets in immune responses. In addition, recent studies have shown that the interaction between CCL5 and CCR5 is involved in various pathological processes including inflammation, chronic diseases, cancers as well as the infection of COVID-19. This review focuses on how CCL5/CCR5 axis participates in the pathological processes of different diseases and their relevant signaling pathways for the regulation of the axis. Moreover, we highlighted the gene therapy and chemotherapy studies for treating CCR5-related diseases, including the ongoing clinical trials. The barriers and perspectives for future application and translational research were also summarized.

show abstract

“…The interplay between MDSCs and Tregs contribute to the establishment of an immunosuppressive environment. MDSCs promote the production of Tregs via a cell-contact dependent mechanism, inducing immune tolerance under conditions of cancers or other abnormal immune responses [ 50 , 51 ]. In addition, MDSCs also directly incite tumor-associated macrophages (TAMs) to facilitate immunosuppression [ 52 ].…”

Section: Mdscs As the Main Component Of Cellular Immune Suppressorsmentioning

confidence: 99%

Myeloid-Derived Suppressor Cells in Solid Tumors

Renz

Ilmer

et al. 2022

Cells

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) are one of the main suppressive cell population of the immune system. They play a pivotal role in the establishment of the tumor microenvironment (TME). In the context of cancers or other pathological conditions, MDSCs can differentiate, expand, and migrate in large quantities during circulation, inhibiting the cytotoxic functions of T cells and NK cells. This process is regulated by ROS, iNOS/NO, arginase-1, and multiple soluble cytokines. The definition of MDSCs and their phenotypes in humans are not as well represented as in other organisms such as mice, owing to the absence of the cognate molecule. However, a comprehensive understanding of the differences between different species and subsets will be beneficial for clarifying the immunosuppressive properties and potential clinical values of these cells during tumor progression. Recently, experimental evidence and clinical investigations have demonstrated that MDSCs have a close relationship with poor prognosis and drug resistance, which is considered to be a leading marker for practical applications and therapeutic methods. In this review, we summarize the remarkable position of MDSCs in solid tumors, explain their classifications in different models, and introduce new treatment approaches to target MDSCs to better understand the advancement of new approaches to cancer treatment.

show abstract

Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell Interaction

Cited by 13 publications

References 136 publications

Uncovering the Subtype-Specific Molecular Characteristics of Breast Cancer by Multiomics Analysis of Prognosis-Associated Genes, Driver Genes, Signaling Pathways, and Immune Activity

Uncovering the Subtype-Specific Molecular Characteristics of Breast Cancer by Multiomics Analysis of Prognosis-Associated Genes, Driver Genes, Signaling Pathways, and Immune Activity

CCL5/CCR5 axis in human diseases and related treatments

Myeloid-Derived Suppressor Cells in Solid Tumors

Contact Info

Product

Resources

About